Research ArticleOriginal Article
Open Access

FDX1 expression promotes DSF/Cu-induced cuproptosis in gastric cancer cells

Qirong Li, Yi Guo, Jiahuan Yuan, Qiang Feng, Hengzong Zhou, Ming Hao, Boqiang Tao, Liqun Sun, Chao Lin, Jianfeng Mu, Gongliang Guo and Dongxu Wang
Cancer Biology & Medicine July 2026, 20250323; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0323

References

  1. 1.↵
    2. Ge EJ,
    3. Bush AI,
    4. Casini A,
    5. Cobine PA,
    6. Cross JR,
    7. DeNicola GM, et al.
    Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022; 22: 102–13.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Tsvetkov P,
    3. Coy S,
    4. Petrova B,
    5. Dreishpoon M,
    6. Verma A,
    7. Abdusamad M, et al.
    Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022; 375: 1254–61.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Xie J,
    3. Yang Y,
    4. Gao Y,
    5. He J.
    Cuproptosis: mechanisms and links with cancers. Mol Cancer. 2023; 22: 46.
    OpenUrlPubMed
  4. 4.↵
    2. Yan JN,
    3. Guo LH,
    4. Zhu DP,
    5. Ye GL,
    6. Shao YF,
    7. Zhou HX.
    Clinical significance and potential application of cuproptosis-related genes in gastric cancer. World J Gastrointest Oncol. 2023; 15: 1200–14.
    OpenUrlPubMed
  5. 5.↵
    2. Schapira M,
    3. Tyers M,
    4. Torrent M,
    5. Arrowsmith CH.
    WD40 repeat domain proteins: a novel target class? Nat Rev Drug Discov. 2017; 16: 773–86.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Sun H,
    3. Sun Q,
    4. Qiu X,
    5. Zhang G,
    6. Chen G,
    7. Li A, et al.
    WD repeat domain 43 promotes malignant progression of non-small cell lung cancer by regulating CDK2. Int J Biochem Cell Biol. 2022; 151: 106293.
  7. 7.↵
    2. Li Z,
    3. Feng M,
    4. Zhang J,
    5. Wang X,
    6. Xu E,
    7. Wang C, et al.
    WD40 repeat 43 mediates cell survival, proliferation, migration and invasion via vimentin in colorectal cancer. Cancer Cell Int. 2021; 21: 418.
    OpenUrlPubMed
  8. 8.↵
    2. Di Y,
    3. Jing X,
    4. Hu K,
    5. Wen X,
    6. Ye L,
    7. Zhang X, et al.
    The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity. Drug Resist Updat. 2023; 66: 100909.
  9. 9.↵
    2. Siegel RL,
    3. Miller KD,
    4. Fuchs HE,
    5. Jemal A.
    Cancer statistics, 2021. CA Cancer J Clin. 2021; 71: 7–33.
    OpenUrlCrossRefPubMed
  10. 10.↵
    2. Wang Y,
    3. Zhang L,
    4. Yang Y,
    5. Lu S,
    6. Chen H.
    Progress of gastric cancer surgery in the era of precision medicine. Int J Biol Sci. 2021; 17: 1041–9.
    OpenUrlPubMed
  11. 11.↵
    2. Guan WL,
    3. He Y,
    4. Xu RH.
    Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023; 16: 57.
    OpenUrlCrossRefPubMed
  12. 12.↵
    2. Skrott Z,
    3. Mistrik M,
    4. Andersen KK,
    5. Friis S,
    6. Majera D,
    7. Gursky J, et al.
    Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017; 552: 194–9.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Liu W,
    3. Xiang H,
    4. Tan M,
    5. Chen Q,
    6. Jiang Q,
    7. Yang L, et al.
    Nanomedicine enables drug-potency activation with tumor sensitivity and hyperthermia synergy in the second near-infrared biowindow. ACS Nano. 2021; 15: 6457–70.
    OpenUrlPubMed
  14. 14.↵
    2. Liu Y,
    3. Guan X,
    4. Wang M,
    5. Wang N,
    6. Chen Y,
    7. Li B, et al.
    Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways. Bioengineered. 2022; 13: 6579–89.
    OpenUrlPubMed
  15. 15.↵
    2. Zhou J,
    3. Yu Q,
    4. Song J,
    5. Li S,
    6. Li XL,
    7. Kang BK, et al.
    Photothermally triggered copper payload release for cuproptosis-promoted cancer synergistic therapy. Angew Chem Int Ed Engl. 2023; 62: e202213922.
  16. 16.↵
    2. Wu W,
    3. Yu L,
    4. Jiang Q,
    5. Huo M,
    6. Lin H,
    7. Wang L, et al.
    Enhanced tumor-specific disulfiram chemotherapy by In Situ Cu2+ chelation-initiated nontoxicity-to-toxicity transition. J Am Chem Soc. 2019; 141: 11531–9.
    OpenUrlPubMed
  17. 17.↵
    2. Wu P,
    3. Zhang B,
    4. Ocansey DKW,
    5. Xu W,
    6. Qian H.
    Extracellular vesicles: a bright star of nanomedicine. Biomaterials. 2021; 269: 120467.
  18. 18.↵
    2. Krzewski K,
    3. Coligan JE.
    Human NK cell lytic granules and regulation of their exocytosis. Front Immunol. 2012; 3: 335.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Kang YT,
    3. Niu Z,
    4. Hadlock T,
    5. Purcell E,
    6. Lo TW,
    7. Zeinali M, et al.
    On-chip biogenesis of circulating NK cell-derived exosomes in non-small cell lung cancer exhibits antitumoral activity. Adv Sci (Weinh). 2021; 8: 2003747.
  20. 20.↵
    2. Wen C,
    3. Seeger RC,
    4. Fabbri M,
    5. Wang L,
    6. Wayne AS,
    7. Jong AY.
    Biological roles and potential applications of immune cell-derived extracellular vesicles. J Extracell Vesicles. 2017; 6: 1400370.
  21. 21.↵
    2. Lugini L,
    3. Cecchetti S,
    4. Huber V,
    5. Luciani F,
    6. Macchia G,
    7. Spadaro F, et al.
    Immune surveillance properties of human NK cell-derived exosomes. J Immunol. 2012; 189: 2833–42.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    2. Xue Q,
    3. Kang R,
    4. Klionsky DJ,
    5. Tang D,
    6. Liu J,
    7. Chen X.
    Copper metabolism in cell death and autophagy. Autophagy. 2023; 19: 2175–95.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Chong W,
    3. Ren H,
    4. Chen H,
    5. Xu K,
    6. Zhu X,
    7. Liu Y, et al.
    Clinical features and molecular landscape of cuproptosis signature-related molecular subtype in gastric cancer. Imeta. 2024; 3: e190.
  24. 24.↵
    2. Smyth EC,
    3. Nilsson M,
    4. Grabsch HI,
    5. van Grieken NC,
    6. Lordick F.
    Gastric cancer. Lancet. 2020; 396: 635–48.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Chen L,
    3. Min J,
    4. Wang F.
    Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target Ther. 2022; 7: 378.
    OpenUrlPubMed
  26. 26.↵
    2. Oliveri V.
    Selective targeting of cancer cells by copper ionophores: an overview. Front Mol Biosci. 2022; 9: 841814.
  27. 27.↵
    2. Tang D,
    3. Chen X,
    4. Kroemer G.
    Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022; 32: 417–8.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Cao Z,
    3. Hou Y,
    4. Zhao Z,
    5. Zhang H,
    6. Tian L,
    7. Zhang Y, et al.
    Reactivating Hippo by drug compounds to suppress gastric cancer and enhance chemotherapy sensitivity. J Biol Chem. 2024; 300: 107311.
  29. 29.↵
    2. MacDonagh L,
    3. Gallagher MF,
    4. Ffrench B,
    5. Gasch C,
    6. Breen E,
    7. Gray SG, et al.
    Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. Oncotarget. 2017; 8: 72544–72563.
    OpenUrlCrossRefPubMed
  30. 30.↵
    2. Wang J,
    3. Qin D,
    4. Tao Z,
    5. Wang B,
    6. Xie Y,
    7. Wang Y, et al.
    Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Front Immunol. 2022; 13: 1056932.
  31. 31.↵
    2. Sun L,
    3. Zhang Y,
    4. Yang B,
    5. Sun S,
    6. Zhang P,
    7. Luo Z, et al.
    Lactylation of METTL16 promotes cuproptosis via m6a-modification on FDX1 mRNA in gastric cancer. Nat Commun. 2023; 14: 6523.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Liu J,
    3. Ren L,
    4. Li S,
    5. Li W,
    6. Zheng X,
    7. Yang Y, et al.
    The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B. 2021; 11: 2783–97.
    OpenUrlPubMed
  33. 33.↵
    2. Lettau M,
    3. Schmidt H,
    4. Kabelitz D,
    5. Janssen O.
    Secretory lysosomes and their cargo in T and NK cells. Immunol Lett. 2007; 108: 10–9.
    OpenUrlCrossRefPubMed
  34. 34.↵
    2. Iliopoulou EG,
    3. Kountourakis P,
    4. Karamouzis MV,
    5. Doufexis D,
    6. Ardavanis A,
    7. Baxevanis CN, et al.
    A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010; 59: 1781–9.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Shah NN,
    3. Baird K,
    4. Delbrook CP,
    5. Fleisher TA,
    6. Kohler ME,
    7. Rampertaap S, et al.
    Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood. 2015; 125: 784–92.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    2. Théry C,
    3. Witwer KW,
    4. Aikawa E,
    5. Alcaraz MJ,
    6. Anderson JD,
    7. Andriantsitohaina R, et al.
    Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018; 7: 1535750.
  37. 37.↵
    2. Ma CY,
    3. Zhai Y,
    4. Li CT,
    5. Liu J,
    6. Xu X,
    7. Chen H, et al.
    Translating mesenchymal stem cell and their exosome research into GMP compliant advanced therapy products: promises, problems and prospects. Med Res Rev. 2024; 44: 919–38.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords